Amgen combination cuts death risk in Phase 3 small cell lung cancer study
In a Phase 3 trial, Amgen's Imdelltra plus AstraZeneca's Imfinzi reduced the risk of death by 58% compared with Imfinzi alone among certain small cell lung cancer patients receiving first-line maintenance treatment. The combination surpassed the trial's efficacy benchmark.
The Phase 3 result focuses on first-line maintenance treatment for a certain group of small cell lung cancer patients. In that setting, adding Amgen’s Imdelltra to AstraZeneca’s Imfinzi was linked to a 58% lower risk of death than Imfinzi alone. The combination also exceeded the trial’s efficacy benchmark. These findings apply to the described patient group and treatment phase, and the comparison is against Imfinzi monotherapy.
If the benefit holds in broader use, this combination could matter most to patients with the described small cell lung cancer subtype and their caregivers, who may face limited maintenance options. Clinicians may gain another option to discuss, while health systems could weigh access, cost, and delivery logistics. The trial result alone does not establish real-world effectiveness, so its societal impact may depend on further evidence and how quickly the regimen becomes available.